诺和诺德以10亿美元收购Lexicon的LX9851，以扩大减肥药物组合-动脉网

Novo Nordisk Acquires Lexicon’s LX9851 for $1B to Expand Weight Loss Drug Portfolio Related posts:

GeneOnline 等信源发布 2025-04-04 13:18



可切换为仅中文







by Steven Chung

作者：史蒂文·钟

Share To

分享到

Novo Nordisk’s Wegovy (semaglutide) faces strong competition from Eli Lilly and Company’s Zepbound (tirzepatide), a dual GLP-1/GIP agonist. Image: Novo Nordick

诺和诺德的Wegovy（司美格鲁肽）面临来自礼来公司的Zepbound（替尔泊肽）的激烈竞争，后者是一种双重GLP-1/GIP激动剂。图片来源：诺和诺德

exicon Pharmaceuticals (Lexicon), a U.S. biopharmaceutical company, announced recently in The Woodlands, Texas, that it has entered into an exclusive licensing agreement with Danish pharmaceutical giant Novo Nordisk. Under the agreement, Novo Nordisk gains global exclusive rights to develop, manufacture, and commercialize LX9851, a novel oral non-incretin candidate targeting obesity and related metabolic disorders.

Lexicon Pharmaceuticals（Lexicon），一家美国生物制药公司，最近在德克萨斯州伍德兰兹宣布，已与丹麦制药巨头诺和诺德达成独家许可协议。根据协议，诺和诺德获得了一款新型口服非肠促胰岛素候选药物LX9851的全球独家权利，该药物针对肥胖及相关代谢疾病。

Lexicon will complete mutually agreed-upon IND-related activities, while Novo Nordisk will be responsible for filing the IND application. The deal includes an upfront payment and near-term milestone payments totaling up to US$75 million. With additional payments for development, regulatory milestones, and commercial success, Lexicon could receive up to US$1 billion.

Lexicon将完成双方商定的与IND相关的活动，而诺和诺德将负责提交IND申请。该协议包括一笔首付款和近期的里程碑付款，总计高达7500万美元。随着开发、监管里程碑和商业成功的额外付款，Lexicon可能获得高达10亿美元的收入。

Furthermore, Lexicon will earn tiered royalties on LX9851’s net sales..

此外，Lexicon 将根据 LX9851 的净销售额获得分级特许权使用费。

LX9851’s Novel Mechanism Enhances Semaglutide Efficacy

LX9851的新机制增强司美格鲁肽的疗效

LX9851, discovered and developed by

LX9851，由以下机构发现并开发：

Lexicon

词典

，

is a highly potent and selective oral small molecule inhibitor of acyl-CoA synthetase 5 (ACSL5), a key enzyme in fat accumulation and energy balance regulation. LX9851 may also activate the ileal brake mechanism, delaying gastric emptying, suppressing appetite, and enhancing satiety. Preclinical in vivo data presented at Obesity Week 2024 .

是一种高效且选择性的酰基辅酶A合成酶5（ACSL5）口服小分子抑制剂，ACSL5是脂肪积累和能量平衡调节的关键酶。LX9851还可能激活回肠制动机制，延缓胃排空，抑制食欲并增强饱腹感。在2024年肥胖周上展示了临床前体内数据。

showed

显示

that LX9851, when combined with semaglutide, significantly reduced body weight, food intake, and fat mass compared to semaglutide alone. Additionally, after discontinuation of semaglutide, introducing LX9851 effectively prevented weight gain again and improved liver steatosis.

LX9851与司美格鲁肽联合使用时，与单独使用司美格鲁肽相比，显著减轻了体重、食物摄入量和脂肪量。此外，在停止使用司美格鲁肽后，引入LX9851有效防止了体重反弹，并改善了肝脂肪变性。

Dr. Mike Exton, CEO and Director of Lexicon,

Lexicon公司首席执行官兼董事迈克·埃克斯顿博士，

stated

声明

, “We are pleased that Novo Nordisk, a global leader in diabetes and obesity treatment, recognizes the potential of LX9851. This collaboration strengthens our financial position, enabling greater flexibility to invest in R&D and accelerate innovation.”

“我们很高兴全球糖尿病和肥胖治疗领域的领导者诺和诺德认识到LX9851的潜力。此次合作增强了我们的财务状况，使我们能够更灵活地投资于研发并加速创新。”

Jacob Sten Petersen, Senior Vice President of Diabetes, Obesity, and MASH at Novo Nordisk,

诺和诺德糖尿病、肥胖症和MASH高级副总裁雅各布·斯坦·彼得森，

commented

已评论

, “

， “

Novo Nordisk

诺和诺德

is committed to addressing the diverse needs of patients with obesity and metabolic disorders by building a differentiated pipeline of innovative treatments. We are excited to collaborate with Lexicon to further explore new biological mechanisms and potential therapies, building upon Lexicon’s excellent research foundation for LX9851.”.

致力于通过构建多样化的创新治疗管线来满足肥胖和代谢紊乱患者的多样化需求。我们很高兴与Lexicon合作，进一步探索新的生物学机制和潜在疗法，基于Lexicon对LX9851的优秀研究基础。”

Semaglutide Shows Improved Mobility in Diabetic Patients

Semaglutide 显示出糖尿病患者活动能力的改善

A study published on March 29 in

一项研究于3月29日发表

The Lancet

柳叶刀

revealed

揭示

that semaglutide significantly increased walking distance in patients with symptomatic peripheral artery disease (PAD) and type 2 diabetes. These findings suggest the need for further research into its beneficial mechanisms and its potential efficacy and safety in PAD patients without diabetes.

司美格鲁肽可显著增加症状性外周动脉疾病（PAD）和2型糖尿病患者的步行距离。这些研究结果表明，有必要进一步研究其有益机制，以及在非糖尿病的PAD患者中的潜在疗效和安全性。

Additionally,

此外，

The New England Journal of Medicine

新英格兰医学杂志

published another study on March 29. It

于3月29日发表了另一项研究。它

showed

显示了

that oral semaglutide use in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), or both was associated with a significant reduction in major adverse cardiovascular events (MACE) without increasing serious adverse events.

口服司美鲁肽用于治疗伴有动脉粥样硬化性心血管疾病 (ASCVD)、慢性肾病 (CKD) 或两者兼有的 2 型糖尿病患者时，可显著减少主要不良心血管事件 (MACE)，且不会增加严重不良事件。

Eli Lilly and Novo Nordisk Locked in Escalating Weight Loss Drug Rivalry

礼来和诺和诺德在减肥药竞争中陷入日益激烈的对抗

This marks Novo Nordisk’s second major weight loss drug licensing deal in recent weeks. On March 24, Novo Nordisk secured another weight loss drug from The United Laboratories International, a Chinese pharmaceutical company, with an upfront payment of US$200 million and a total potential deal value of up to .

这标志着诺和诺德在最近几周内的第二笔重大减肥药物许可交易。3月24日，诺和诺德从中国制药公司联邦实验室国际获得了另一种减肥药物，预付款为2亿美元，总潜在交易价值高达。

US$1.8

1.8美元

billion.

十亿。

Novo Nordisk’s

诺和诺德的

Wegovy

诺和盈

(semaglutide) faces strong competition from Eli Lilly and Company’s Zepbound (tirzepatide), a dual GLP-1/GIP agonist, which has demonstrated superior weight loss efficacy in clinical trials. Despite Wegovy generating approximately

（司美鲁肽）面临来自礼来公司 Zepbound（替尔泊肽）的激烈竞争，Zepbound 是一种双重 GLP-1/GIP 激动剂，在临床试验中展现了更优越的减重效果。尽管 Wegovy 产生了大约

US$8

8美元

billion in annual revenue, Zepbound’s stronger clinical performance has intensified competition. To maintain its leadership in the obesity market and related indications, Novo Nordisk is actively acquiring promising weight loss drug candidates and building a diversified and differentiated pipeline to address future market challenges..

每年因Zepbound的强劲临床表现加剧了竞争。为了保持其在肥胖症市场及相关适应症领域的领先地位，诺和诺德正在积极收购有前景的减肥药物候选药物，并建立多元化和差异化的研发管线，以应对未来的市场挑战。